Transform how you analyse drug development risk
With the only transparent analysis of drug development risk at the product level.
$242bn forecasted orphan drug sales by 2024, one-fifth of the total worldwide pharmaceutical market
The EvaluatePharma Orphan Drug Report 2019 arrives at the start of a new era the orphan drug industry, following the FDA’s approval of the first gene therapy product. Coupled with other breakthrough cell therapy products, the orphan drug market is poised to capitalise on cutting-edge science to the tune of a 12% CAGR to 2024, double the 6% rate expected for non-orphan products.